Customize your JAMA Network experience by selecting one or more topics from the list below.
To the Editor.—
Report of a Case.—
A 67-year-old man with a history of parkinsonism, successfully managed with levodopa therapy since 1981, noted a superior visual field deficit in the right eye in 1982. Our evaluation disclosed an inferior choroidal malignant melanoma with a large, overlying sensory retinal detachment. Results of metastatic workups, at that time and since, have been normal. The patient was treated with placement of a cobalt 60 plaque over the tumor, delivering a total apex radiation dose of 10,000 rad over the 10-mm tumor base. During the course of the following eight months, the tumor substantially decreased in size and vision was restored.
The case reports by Skibba1 and others2-4 have stimulated a growing concern in the relationship between dihydroxyphenylalanine therapy and the occurrence of malignant melanoma, uveal or cutaneous. These reports discussed patients with parkinsonism treated with levodopa who subsequently suffered recurrence of
Abramson DH, Rubenfeld MR. Choroidal Melanoma and Levodopa. JAMA. 1984;252(8):1011–1012. doi:10.1001/jama.1984.03350080017013
Coronavirus Resource Center
Create a personal account or sign in to: